The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Lisaftoclax ramp-up combined with acalabrutinib or rituximab in patients with CLL/SLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential benefits of lisaftoclax as a safer alternative to venetoclax for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly in patients with prior exposure to venetoclax. In a Phase Ib/II study exploring lisaftoclax alone or in combination with acalabrutinib or rituximab, lisaftoclax demonstrated good activity and efficacy, with a high overall response rate (ORR), especially when combined with acalabrutinib. This study has informed the design of a Phase III trial. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Merck: Consultancy; MEI Pharma: Research Funding; AbbVie: Consultancy, Research Funding; Eli Lilly: Consultancy; AstraZeneca: Consultancy, Research Funding; BeiGene: Consultancy; Ascentage Pharma: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Surface Technology: Research Funding; Adaptive Biosciences: Consultancy; Janssen: Consultancy; Genmab: Consultancy; BMS: Consultancy; Novartis: Research Funding; Genentech: Consultancy, Research Funding.
